Skip to main content
Premium Trial:

Request an Annual Quote

Isis Sued over Stock Drop following Kynamro Safety Report by FDA

Premium

Isis Pharmaceuticals and its top executives have been sued as part of class action litigation over allegedly misleading claims made about the company's investigational cholesterol drug Kynamro and the subsequent drop in the firm's stock price following a troubling regulatory review of the agent.

According to the lawsuit, which was filed on behalf of Isis investors, Isis and its management made “materially false and misleading statements regarding the safety and efficacy of the product, as well as reportedly positive results from Kynamro’s clinical trials.”

However, in October, the US Food and Drug Administration published a clinical briefing document noting the incidence of abnormal growths or neoplasms in some patients treated with the drug, which has been submitted as a treatment for homozygous familial hypercholesterolemia. The report also found that three patients treated with Kynamro had died during clinical testing.

As a result, shares of Isis dropped nearly 22 percent to $10.27 on Oct. 16. This week, the stock was trading around $10.75.

Even though an FDA advisory committee later recommended the drug for approval by a split vote, the lawsuit states that Isis investors suffered “significant damages” due to the company's failure to disclose Kynamro's safety issues.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.